ExpreS2ion Biotech Holding AB (SE:EXPRS2)

:EXPRS2

EXPRS2

ExpreS2ion Biotech Holding AB

RESEARCH TOOLSreports

Want to see SE:EXPRS2 full AI Analyst Report?

ExpreS2ion Biotech Holding AB (EXPRS2) Price & Analysis

0 Followers

EXPRS2 Stock Chart & Stats

kr17.10

-kr1.20(-4.51%)

At close: Mar 06 4:00 PM EST

kr17.10

-kr1.20(-4.51%)

Day’s Range― - ―

52-Week Rangekr1.36 - kr12.22

Previous CloseN/A

Volume135.00

Average Volume (3M)19.88K

Market Cap

kr65.05M

Enterprise Value-kr40.54M

Total Cash (Recent Filing)kr47.55M

Total Debt (Recent Filing)kr2.21M

Price to Earnings (P/E)―

Beta1.27

Next Earnings

May 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-13.66

Shares Outstanding23,398,983

10 Day Avg. Volume26,629

30 Day Avg. Volume19,883

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.27

Price to Sales (P/S)12.37

P/FCF Ratio-1.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-9.64

Revenue Forecast (FY)kr10.00M

Bulls Say, Bears Say

Bulls Say

Specialized Protein-expression PlatformExpreS2ion's core platform focuses on producing hard-to-express antigens, a technical niche with high barriers to entry. That specialization creates client stickiness and defensibility versus generalist providers, supporting sustained contract demand from vaccine and antibody R&D programs.

Fee-for-service Plus CollaborationsA mixed model of fee-for-service projects and collaboration arrangements delivers multiple non-product revenue streams. Fee-based work yields recurring project cashflows tied to client pipelines, while collaborations can supply milestone and royalty upside, diversifying funding sources over time.

Low Financial LeverageReported very low debt levels provide financial flexibility for a development-stage biotech. Low leverage reduces fixed financing costs and lowers solvency risk, making it easier to raise capital or absorb temporary setbacks without heavy interest burdens, preserving runway capacity.

Bears Say

Persistent Negative Cash FlowConsistent negative operating and free cash flow indicates the business consumes cash rather than self-funds growth. Worsening FCF in 2025 raises reliance on external financing, heightens dilution risk, and constrains the company's ability to invest in capacity, platform scaling, or sustained R&D programs.

Structurally Loss-making OperationsRecurrent operating and net losses with deeply negative margins limit internal reinvestment and pressure the equity base. Structural unprofitability increases the need for external capital, reduces resilience to funding shocks, and means management must deliver material margin improvement to reach sustainability.

Small, Volatile And Shrinking RevenueA small, volatile and recently declining top line undermines scale economics and predictability of cash flow. Without reliable revenue growth, fixed R&D and manufacturing costs are harder to cover, making it difficult to achieve break-even and increasing execution and funding risk over the medium term.

EXPRS2 FAQ

What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?

ExpreS2ion Biotech Holding AB lowest stock price was kr1.36 and its highest was kr12.22 in the past 12 months.

What is ExpreS2ion Biotech Holding AB’s market cap?

ExpreS2ion Biotech Holding AB’s market cap is kr65.05M.

When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?

ExpreS2ion Biotech Holding AB’s upcoming earnings report date is May 28, 2026 which is in 5 days.

How were ExpreS2ion Biotech Holding AB’s earnings last quarter?

ExpreS2ion Biotech Holding AB released its earnings results on Feb 19, 2026. The company reported -kr0.859 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.859.

Is ExpreS2ion Biotech Holding AB overvalued?

According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ExpreS2ion Biotech Holding AB pay dividends?

ExpreS2ion Biotech Holding AB does not currently pay dividends.

What is ExpreS2ion Biotech Holding AB’s EPS estimate?

ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ExpreS2ion Biotech Holding AB have?

ExpreS2ion Biotech Holding AB has 23,398,983 shares outstanding.

What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?

ExpreS2ion Biotech Holding AB reported an EPS of -kr0.859 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.283%.

Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?

Currently, no hedge funds are holding shares in SE:EXPRS2

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ExpreS2ion Biotech Holding AB

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.